Help us make childhood cancer universally survivable.

By giving monthly, you directly support our continued research into discovering effective and less toxic treatments for childhood cancer.

Support Our Lab

$
Select Payment Method
Personal Info

Credit Card Info
This is a secure SSL encrypted payment.
Billing Details

I want to dedicate this donation to someone

In honor of... Details

Donation Total: $25.00 One Time

{amount} donation plus {fee_amount} to help cover fees.

Our team of scientists and engineers are on a mission...

We are a nonprofit biotech lab on a mission to make childhood cancer universally survivable. Every year, the FDA approves on average 12 drugs to treat adult cancer, but has only approved 6 drugs to treat childhood cancer since 1978. We believe it’s time to do better. 

Learn More About Our Research

Let's do better for

#letsdobetter

Latest News

Science Nonfiction: Samuel, Hepatoblastoma & Quail Assays

Samuel Rasmussen October 3, 2018

I am working towards a cure for hepatoblastoma by testing medicines on a quail assay I have been developing. My work focuses on a quail assay used to test drugs on hepatoblastoma. The first trial in building the quail assay is to have a reliable way to prepare the eggs. The original method required a great deal of dexterity and was typically performed by one our more skilled lab members with surgical experience. The device I built allows anyone to prepare the eggs after just one training session. Next, I had to get the tumors

Read More »
View All Blog Posts

Current Research Projects

The "Alexa" Project
The goal of The Alexa Project is to find new treatments to move towards clinical trials for all children affected with the neurofibromatosis-1 (NF1) associated brain tumors called juvenile pilocytic astrocytoma (JPA).
Learn More »
Big Data Analytics of a massive drug screen by Cell of Origin
We have partnered with a major pharmaceutical company to conduct an unprecedented screen of more than 640,000 compounds that, when combined, could offer new treatments for pediatric cancers that haven’t seen progress in decades.
Learn More »
The Functional Genomics of Wilms’ Tumor
Our Wilms’ tumor studies are led by Andy Woods, dad to Stellablue Woods, who was diagnosed with anaplastic Wilms’ tumor when she was just 4 years old. Andy brings the motivation of an impassioned father to our study, and is inspired by his personal experience with pediatric cancer to bring about better treatment options for children like his daughter.
Learn More »
Epigenetic Therapy to Overcome Checkpoint Adaptation in Rhabdomyosarcoma
Our team has identified a cancer-causing gene (also known as an oncogene) called Pax3:Foxo1 that causes current treatments to fail. Remarkably, Pax3:Foxo1 can silenced by entinostat, a drug recently granted FDA breakthrough designation for breast cancer.
Learn More »
Be a Dog’s Best Friend, Help a Child
To make it better for children & young adults with osteosarcoma, cc-TDI is exploring the types of non-chemotherapy drugs that re-program osteosarcoma tumor cells to stop growing – or cease to exist.
Learn More »
Next Steps in the Rapid Preclinical Development of a Targeted Therapy Combination for Diffuse Intrinsic Pontine Glioma (DIPG)
Remarkably, this is the first time that a group of basic and translational scientists and physicians from institutions throughout North America and Europe have come together as a consortium to focus on a bench-to-bedside approach to rationally target therapy for children with DIPG.
Learn More »

A dedicated research team

Our research team is exploring and testing state-of-the-art treatment options for the most urgent issues facing children with cancer. 

Working in our own freestanding research institution allows us to act swiftly and nimbly to achieve results—bringing cost control, speed, purpose, and focus to translate effective treatments into the clinic. To get there, we perform basic science and translational research in our industrial modern lab site (a paint factory remodeled by Nike as an off-site creative space), adjacent to the Silicon Forest in Oregon.

Meet the Team

Navigation

Contact

More Information

EIN: 46-5759569

cc-TDI is a qualified 501(c)(3) charitable organization registered with the IRS
(consult with a CPA regarding specific tax implications)

 

Copyright 2018 – Children’s Cancer Therapy Development Institute
Close Menu